You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
樂普醫療(300003.SZ):上半年扣非淨利預增15%-35%
格隆匯 07-06 16:07

格隆匯 7 月 6日丨樂普醫療(300003.SZ)披露2020年半年度業績預告,預計歸屬於上市公司股東的淨利潤約10.4億元–約12.71億元,同比變動-10%-10%;預計歸屬於上市公司股東的扣除非經常性損益的淨利潤約10.58億元–約12.41億元,同比增長15%-35%。業績變動原因如下:

1、報告期內,年初受新冠肺炎疫情影響,植入器械和醫療服務整體業績較同期大幅下降。進入二季度隨着國內新冠肺炎疫情的好轉,植入器械和醫療服務已呈現良好的增長態勢;新冠疫情相關產品的出口也貢獻了相應的業績,二季度器械相關營銷收入較去年同期增長60%以上;藥品業務,由於集採銷售額有所波動,但利潤也有所成長。二季度利潤較上年同期增長35%-70%。綜合一二季度經營情況,上半年主營業務所帶來的歸屬於上市公司股東的扣非淨利潤預計較上年同期有15%-35%之間的增長。

2、報告期內,預計非經常性損益對公司歸屬於上市公司股東的淨利潤影響金額約2000.00萬元,上年同期主要由於上海君實生物醫藥科技股份有限公司的相關收益形成的非經常性損益約2.36億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account